A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.

Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. (1/2394)

PURPOSE: To define the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with mitoxantrone in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: Forty-one chemotherapy-naive patients with MBC (median age, 61 years) were enrolled. Thirty-eight (93%) had performance status (World Health Organization [WHO]) 0, 29 (71%) were postmenopausal, and 21 (51%) had estrogen receptor-negative tumors. Patients received escalated doses of docetaxel (75 to 100 mg/m2) on day 1 and mitoxantrone (8 to 22 mg/m2) on day 8. Treatment was repeated every 3 weeks. RESULTS: A total of 217 chemotherapy cycles were administered. Without recombinant human granulocyte colony-stimulating factor (rhG-CSF) support, the MTD1 occurred at the first dose level (docetaxel 75 mg/m2 and mitoxantrone 8 mg/m2); DLTs were febrile neutropenia, grade 4 neutropenia lasting more than 5 days, and grade 3 diarrhea. With prophylactic rhG-CSF, the MTD2 was docetaxel 100 mg/m2 and mitoxantrone 20 mg/m2; DLTs were febrile neutropenia and grade 4 neutropenia. Nine (22%) patients developed neutropenia after the first cycle of treatment. A total of 19 episodes of febrile neutropenia (9% of the cycles) occurred during the whole period of the study; there were no toxic deaths. At high docetaxel (100 mg/m2) and mitoxantrone (> 12 mg/m2) dose levels, a significant decrease of the absolute lymphocyte number was observed; immunophenotyping revealed that all lymphocyte subpopulations were reduced. Grades 2 and 3 neurosensory toxicity occurred in six patients (15%) and one patient (2%), respectively. No cardiac toxicity was observed. Nine complete responses (22%) and 23 partial responses (56%) were achieved (overall response rate, 78%; 95% confidence interval, 62.5% to 88.8%). The median duration of response was 12.5 months, and the median time to tumor progression was 14.5 months. CONCLUSION: The reported combination of docetaxel and mitoxantrone with G-CSF support is a safe, intensified, well-tolerated, and effective regimen as first-line treatment in patients with MBC.  (+info)

Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. (2/2394)

PURPOSE: To evaluate the tolerance and efficacy of the combination of docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Fifty-one chemotherapy-naive patients with NSCLC were treated with gemcitabine 900 mg/m2 intravenously on days 1 and 8 and docetaxel 100 mg/m2 intravenously on day 8 with granulocyte colony-stimulating factor (150 microg/m2, subcutaneously) support from day 9 to day 15. Treatment was repeated every 3 weeks. RESULTS: The patients' median age was 64 years. The World Health Organization performance status was 0 to 1 in 39 patients and 2 in 12 patients. Fifteen patients (29%) had stage IIIB disease, and 36 (71%) had stage IV; histology was mainly squamous cell carcinoma (59%). A partial response was achieved in 19 patients (37.5%; 95% confidence interval, 24% to 50%); stable disease and progressive disease were each observed in 16 patients (31.4%). The median duration of response and the time to tumor progression were 5 and 6 months, respectively. The median survival was 13 months, and the actuarial 1-year survival was 50.7%. Grade 4 anemia and thrombocytopenia were rare (2%). Four patients (8%) developed grade 3 or 4 neutropenia, and all were complicated with fever; there was no treatment-related death. Grade 3 or 4 diarrhea occurred in three patients (6%), grade 2 or 3 neurotoxicity in four patients (8%), grade 2 or 3 asthenia in 10 patients (20%), and grade 2 or 3 edema in 10 patients (20%). CONCLUSION: The combination of docetaxel/gemcitabine is well tolerated, can be used for outpatients, and is active for the treatment of advanced NSCLC. This treatment merits further comparison with other cisplatin- or carboplatin-based combinations.  (+info)

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. (3/2394)

PURPOSE: To evaluate the toxicity, efficacy, and pharmacokinetics of docetaxel when combined with oral estramustine and dexamethasone in a phase I study in patients with progressive metastatic androgen-independent prostate cancer. PATIENTS AND METHODS: Thirty-four men were stratified into minimally pretreated (MPT) and extensively pretreated (EPT) groups. Estramustine 280 mg PO tid was administered 1 hour before or 2 hours after meals on days 1 through 5, with escalated doses of docetaxel from 40 to 80 mg/m2 on day 2. Treatment was repeated every 21 days. RESULTS: Thirty-four patients were assessable for toxicity and 33 for response. In the MPT patients, dose-limiting myelosuppression was reached at 80 mg/m2, with six patients experiencing grade 3/4 granulocytopenia. In EPT patients, escalation above 70 mg/m2 was not attempted. Fourteen MPT (70%) and six EPT (50%) patients had a > or = 50% decline in serum PSA on two consecutive measurements taken at least 2 weeks apart. The overall 50% PSA response rate was 63% (95% confidence interval [CI], 28% to 81%). Of the 18 patients with bidimensionally measurable disease, five (28%; 95% CI, 11% to 54%) achieved a partial response. At the time of entry onto the study, 15 patients required narcotic analgesics for bone pain; after treatment, eight (53%) discontinued their pain medications. The area under the curve for docetaxel increased linearly from 40 to 70 mg/m2. At 80 mg/m2, the measured area under the curve was 8.37 (standard deviation, 0.724), which was significantly higher than the previously reported values. CONCLUSION: The recommended phase II dose of docetaxel combined with estramustine is 70 mg/m2 in MPT patients and 60 mg/m2 in EPT patients. This combination is active in men with androgen-independent prostate cancer.  (+info)

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. (4/2394)

BACKGROUND: To apply our preclinical findings of cytotoxic synergy with the combination of estramustine phosphate (EP) and docetaxel as the basis of treatment of hormone refractory metastatic prostate cancer in man. To determine the optimal dosage and the toxicities of these two agents for future trials. PATIENTS AND METHODS: Seventeen patients with hormone refractory metastatic prostate cancer who were ambulatory with performance status < or = 2, normal marrow, renal and hepatic function were entered. Prior exposure to EP or a taxane were exclusion factors. EP was given orally at a dose of 14 mg/kg of body weight daily with concurrent docetaxel administered every 21 days as an intravenous infusion over 1 hour with dexamethasone 8 mg. PO BID for five days. EP dosages were kept static; docetaxel dosages were explored in a minimum of three patients per level for dosages of 40, 60, 70, and 80 mg/m2. Patients were evaluated weekly. Prostate specific antigen (PSA) was measured every three weeks. RESULTS: Five patients were entered at a docetaxel dose of 40 mg/m2, three at 60 mg/m2, six at 70 mg/m2, and three at 80 mg/m2. Only one patient had received prior chemotherapy. Grades 1 or 2 hypocalcemia and hypophosphatemia were seen at all dosage levels. Other grade 2 or less toxicities not related to dosage included alopecia, anorexia, stomatitis, diarrhea, and epigastric pain. Dose limiting toxicities (DLT) as grade 4 leukopenia and grade 4 fatigue were seen at 80 mg/m2. The phase II dose was defined at 70 mg/m2 with rapidly reversible leukopenia and minor liver function abnormalities. At this dosing level, dose intensity was 88% and 86% over consecutive cycles for docetaxel and EP, respectively. Two vascular events occurred at this dose level (70 mg/m2): one arterial and the other venous. PSA decreases greater than 50% from baseline were seen in 14 of 17 patients at all dosage levels. Four of the 17 patients demonstrated a complete biochemical response (PSA < or = 4 ng/ml). One patient had a partial response with measurable lung and liver lesions. CONCLUSION: EP given continuously with every three-week docetaxel at a dose of 70 mg/m2 is tolerable with evidence of antitumor activity based upon significant declines in PSA in the majority of patients and improvement of lung metastasis in one patient. Larger phase II studies of this combination in a homogenous population are warranted.  (+info)

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. (5/2394)

BACKGROUND: Docetaxel and cisplatin are among the most active antitumor agents in head and neck cancer, and phase I studies found the combination of the two drugs to be feasible. The EORTC ECSG performed a multicenter phase II study in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck to evaluate the antitumor efficacy and toxicity of this combination. PATIENTS AND METHODS: Eligibility criteria included written informed consent, a WHO performance status < 2, life expectancy of > 12 weeks, and adequate bone marrow, liver and renal function. Neoadjuvant pretreatment with cisplatin-based chemotherapy or prior radiotherapy were allowed. Patients were ineligible if pretreated with taxoids, had CNS involvement, concurrent malignancy, peripheral neuropathy, or no measurable disease. Treatment consisted of docetaxel 100 mg/m2 (one-hour i.v. infusion), followed by cisplatin 75 mg/m2 (three-hour i.v. infusion), repeated every three weeks. Supportive care included hydration, 5HT3-antagonists, and corticosteroids. RESULTS: Forty-four patients (median age 55 years, range 35-76) entered the trial; 41 patients were eligible, 164 cycles of treatment were evaluable for toxicity, and 31 patients for response. Fourteen patients had undergone prior surgery, 15 had received radiotherapy, and five had had chemotherapy. A median number of four treatment cycles (range 1-6) was given. Hematologic and non-hematologic toxicities were common, but hypersensitivity reactions and fluid retention were very infrequent due to corticosteroid prophylaxis. Four patients were taken off the study due to toxicity, and one toxic death occurred due to pneumonia. Among 41 eligible patients, objective responses as confirmed by independent review included six complete remissions and 16 partial remissions, resulting in an overall response rate of 53.7% (95% confidence interval: 37.4%-69.3%). Responses occurred in locally advanced, recurrent and metastatic disease, both in pre- and non-pretreated patients. Of 22 evaluable, non-pretreated patients with locally advanced or metastatic disease, five achieved complete responses, and 14 partial responses. Observed among nine evaluable pretreated patients with locally advanced or metastatic head and neck cancer were one complete response and two partial responses. CONCLUSION: The combination of docetaxel and cisplatin is feasible and active in locally advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck.  (+info)

Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. (6/2394)

BACKGROUND: Given as first- or second-line chemotherapy docetaxel appears to have great potential in advanced breast cancer. PATIENTS AND METHODS: Three hundred and seventy-seven locally advanced or metastatic breast cancer patients received docetaxel (Taxotere) as part of a named patient programme under the care of 108 oncologists from 61 cancer units across the UK. The recommended starting dose was 100 mg/m2, but patients at higher risk of toxicity started at 75 mg/m2. All patients received corticosteroid premedication. The modal number of prior chemotherapy regimens was 2 (range 1-7). 342 patients (91%) had at least one prior anthracycline-based regimen. RESULTS: Response was graded according to the managing clinician's best judgement without formal criteria. The overall response rate (ORR) was 46% among the 331 evaluable patients. 46% among the 299 patients who were anthracycline resistant and 35% among the 82 patients who were anthracycline refractory (progressive disease being the best response obtained to the most recent anthracycline containing regimen). One hundred and ninety-three patients started at the full dose of 100 mg/m2 with an ORR of 55% and 129 started at 75 mg m2 with an ORR of 33%. In October 1997, some two years after the programme had started, 26 of 377 patients were still alive, although no complete remissions have lasted to this date. Kaplan-Meier survival analysis yielded a median survival of 194 days (95% CI: 178-218 days). Haematological parameters were checked before each course of docetaxel and additionally as clinically indicated. The safety data confirmed that docetaxel has a manageable, predictable side effect profile; 29 of 377 (7.7%) patients were hospitalised as a result of neutropenic sepsis. CONCLUSIONS: The results of this named patient programme over a two year timespan confirm that docetaxel is an effective chemotherapy option in patients with locally advanced and/or metastatic breast cancer, including an 'anthracycline refractory' population.  (+info)

Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. (7/2394)

PURPOSE: The activity of the docetaxel-gemcitabine combination in women with disease progression after initial chemotherapy for metastatic breast cancer (MBC) was investigated in a multicenter phase II study. PATIENTS AND METHODS: Fifty-two patients with metastatic breast cancer who had disease relapse or progression after completion of an anthracycline-based front-line regimen were treated with gemcitabine 900 mg/m2 on day 1 and day 8 and docetaxel 100 mg/m2 on day 8. G-CSF 150 mucg/m2/d s.c. was given from day 9 to day 16 and the treatment was repeated every three weeks. The patients' median age was 57 years and the performance status (WHO) was 0 for 26, 1 for 20 and 2 for 6 patients. The treatment was second-line for 27 (52%) and > or = third-line for 25 (48%) patients. All patients were evaluable for response and toxicity. RESULTS: Complete response occurred in seven (14%) patients and partial response in 21 (40%) for an overall response rate of 54% (95% confidence interval (95% CI): 40%-67%). Fifteen (29%) patients had stable disease and nine (17%) progressive disease. Of 25 patients previously treated with taxanes. 11 (44%) responded (1 CR, 10 PR). Interestingly, in four patients with disease progression while receiving docetaxel or paclitaxel monotherapy, the docetaxel + gemcitabine combination achieved partial responses. Responses were observed at all metastatic sites (local disease 62%, lymph nodes 58%, skin 44%, lung 47% and liver 36%) with a median duration of response of 3.6 months (range 1-16) and a median time to disease progression of eight months (range 2-18.5). Grade 3 neutropenia developed in 10 (19%) and grade 4 in five (10%) patients. Neutropenia was associated with infection in four patients without toxic deaths. Grade 3 thrombocytopenia developed in nine (17%) patients and grade 4 in two (4%). Non-hematologic toxicity was usually mild. CONCLUSION: The docetaxel-gemcitabine combination is an active and well tolerated salvage treatment in patients with MBC. Previous treatment with taxanes does not preclude a good clinical response to this regimen.  (+info)

A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies. (8/2394)

PURPOSE: This study was undertaken to evaluate the feasibility of administering docetaxel (Taxotere; Rhone-Poulenc-Rorer) as a one-hour intravenous (i.v.) infusion on day 1 combined with 5-fluorouracil (5-FU) as a bolus i.v. injection for five (days 1-5) or three (days 1-3) consecutive days every four weeks. PATIENTS AND METHODS: Thirty-seven patients with advanced solid malignancies were treated with 115 total courses involving seven dose levels of the two regimens of docetaxel and 5-FU (docetaxel/5-FU [mg/m2]/mg/m2/d]). In an effort to reduce fluid retention and hypersensitivity phenomena related to docetaxel, patients received premedication with dexamethasone 8 mg orally twice daily for three consecutive days beginning 24 hours before treatment. RESULTS: Severe (grade 4) neutropenia lasting longer than seven days with or without fever and/or severe mucositis, precluded further dose escalation above docetaxel 60 mg/m2 on day 1 and 5-FU 300 mg/m2/day administered on days 1-5 every four weeks. The rates of these toxic effects were also unacceptably high above docetaxel 60 mg/m2 on day 1 and 5-FU 300 mg/m2/day administered on days 1-3 every four weeks. Nine patients experienced various manifestations of fluid-retention that were potentially related to study drugs. However, neither treatment delay nor discontinuation of treatment was required. Nausea, vomiting, diarrhea, and fatigue, were mild to modest in severity and occurred infrequently (< 10% of courses). Two patients with metastatic breast cancer experienced complete responses and a partial response occurred in a patient with metastatic non-small-cell lung cancer. CONCLUSION: Based on the results of this study, the regimen of docetaxel 60 mg/m2 on day 1 followed by 5-FU 300 mg/m2/d i.v. for three or five days every four weeks is well tolerated and these doses are recommended for further evaluations. The feasibility of administering docetaxel 60 mg/m2 followed by 5-FU 300 mg/m2 for three or five days every four weeks and the preliminary antitumor activity noted indicate that further disease-directed studies of docetaxel and 5-FU are warranted in patients with relevant solid malignancies.  (+info)

Taxoids are a class of naturally occurring compounds that are derived from the bark of the Pacific yew tree (Taxus brevifolia) and other species of the genus Taxus. They are known for their antineoplastic (cancer-fighting) properties and have been used in chemotherapy to treat various types of cancer, including ovarian, breast, and lung cancer.

The most well-known taxoid is paclitaxel (also known by the brand name Taxol), which was first discovered in the 1960s and has since become a widely used cancer drug. Paclitaxel works by stabilizing microtubules, which are important components of the cell's skeleton, and preventing them from disassembling. This disrupts the normal function of the cell's mitotic spindle, leading to cell cycle arrest and ultimately apoptosis (programmed cell death).

Other taxoids that have been developed for clinical use include docetaxel (Taxotere), which is a semi-synthetic analogue of paclitaxel, and cabazitaxel (Jevtana), which is a second-generation taxoid. These drugs have similar mechanisms of action to paclitaxel but may have different pharmacokinetic properties or be effective against cancer cells that have developed resistance to other taxoids.

While taxoids have been successful in treating certain types of cancer, they can also cause significant side effects, including neutropenia (low white blood cell count), anemia (low red blood cell count), and peripheral neuropathy (nerve damage). As with all chemotherapy drugs, the use of taxoids must be carefully balanced against their potential benefits and risks.

"Taxus" is a genus of evergreen trees and shrubs, also known as yews. While it is primarily a term used in botanical classification, some species of this plant have medicinal importance. The most notable example is "Taxus brevifolia," or the Pacific Yew, from which the chemotherapy drug Paclitaxel (also known as Taxol) is derived. This drug is used to treat various types of cancer, including ovarian, breast, and lung cancers. It works by interfering with the division of cancer cells. Please note that Paclitaxel must be administered under the supervision of a medical professional, as it can have serious side effects.

Paclitaxel is a chemotherapeutic agent derived from the bark of the Pacific yew tree (Taxus brevifolia). It is an antimicrotubule agent that promotes the assembly and stabilization of microtubules, thereby interfering with the normal dynamic reorganization of the microtubule network that is essential for cell division.

Paclitaxel is used in the treatment of various types of cancer including ovarian, breast, lung, and pancreatic cancers. It works by inhibiting the disassembly of microtubules, which prevents the separation of chromosomes during mitosis, leading to cell cycle arrest and apoptosis (programmed cell death).

Common side effects of paclitaxel include neutropenia (low white blood cell count), anemia (low red blood cell count), alopecia (hair loss), peripheral neuropathy (nerve damage causing numbness or tingling in the hands and feet), myalgias (muscle pain), arthralgias (joint pain), and hypersensitivity reactions.

Antineoplastic agents, phytogenic, also known as plant-derived anticancer drugs, are medications that are derived from plants and used to treat cancer. These agents have natural origins and work by interfering with the growth and multiplication of cancer cells, helping to slow or stop the spread of the disease. Some examples of antineoplastic agents, phytogenic include paclitaxel (Taxol), vincristine, vinblastine, and etoposide. These drugs are often used in combination with other treatments such as surgery, radiation therapy, and other medications to provide a comprehensive approach to cancer care.

Tubulin is a type of protein that forms microtubules, which are hollow cylindrical structures involved in the cell's cytoskeleton. These structures play important roles in various cellular processes, including maintaining cell shape, cell division, and intracellular transport. There are two main types of tubulin proteins: alpha-tubulin and beta-tubulin. They polymerize to form heterodimers, which then assemble into microtubules. The assembly and disassembly of microtubules are dynamic processes that are regulated by various factors, including GTP hydrolysis, motor proteins, and microtubule-associated proteins (MAPs). Tubulin is an essential component of the eukaryotic cell and has been a target for anti-cancer drugs such as taxanes and vinca alkaloids.

Drug screening assays for antitumor agents are laboratory tests used to identify and evaluate the effectiveness of potential drugs or compounds that can inhibit the growth of tumor cells or induce their death. These assays are typically performed in vitro (in a test tube or petri dish) using cell cultures of various types of cancer cells.

The assays measure different parameters such as cell viability, proliferation, apoptosis (programmed cell death), and cytotoxicity to determine the ability of the drug to kill or inhibit the growth of tumor cells. The results of these assays can help researchers identify promising antitumor agents that can be further developed for clinical use in cancer treatment.

There are different types of drug screening assays for antitumor agents, including high-throughput screening (HTS) assays, which allow for the rapid and automated testing of a large number of compounds against various cancer cell lines. Other types of assays include phenotypic screening assays, target-based screening assays, and functional screening assays, each with its own advantages and limitations.

Overall, drug screening assays for antitumor agents play a critical role in the development of new cancer therapies by providing valuable information on the activity and safety of potential drugs, helping to identify effective treatments and reduce the time and cost associated with bringing new drugs to market.

Eisenhauer EA, Vermorken JB (January 1998). "The taxoids. Comparative clinical pharmacology and therapeutic potential". Drugs. ...
Taxoids are usually treated as synonymous with taxanes; for example, a major medical dictionary defines the two terms with the ... Taxoids are chemically taxane-derived diterpenoids, which do occur in nature, in the genera Taxus and Austrotaxus of yew trees ... The taxoids class and the taxanes class both include paclitaxel (trade names Taxol, Abraxane, Onxol, Nov-Onxol) and docetaxel ( ... Taxoids are a class of derivatives from taxol, that is, paclitaxel. They were developed for their anticancer chemotherapeutic ...
... s are usually treated as synonymous with taxoids. The name "taxol" began as a common noun (analogous with other terms in ...
Li, Sheng-Hong; Zhang, Hong-Jie; Niu, Xue-Mei; Yao, Ping; Sun, Han-Dong; Fong, Harry H.S (2003). "Novel taxoids from the ... Taxuyunnanines is a class of taxoids isolated from plants of the genus Taxus. Zhang, Hongjie; Sun, Handong; Takeda, Yoshio ( ... new taxoids from Taxus yunnanensis". Planta Med. 68 (3): 253-7. doi:10.1055/s-2002-23136. PMID 11914964. ...
Shi, QW; Si, XT; Zhao, YM; Yamada, T; Kiyota, H (March 2006). "Two new alkaloidal taxoids from the needles of Taxus canadensis ...
... and third-generation taxoids. The third-generation taxoids showed virtually no difference in potency against drug-resistant and ... Some of the next-generation taxoids also exhibited excellent potency against cancer stem cells. Other highlights include his ... One of his second-generation taxoids, "ortataxel", developed from 14-hydroxy-10-deacetylbaccatin III, and licensed to Indena, ... taxanes and taxoids. This method has been successfully applied for the practical synthesis of the Ojima lactam, a key ...
... is a plant alkaloid and a precursor to the ABC ring system of taxoids. Distinguish from lycaconitine, which is the ...
This structure varies from the 6/8/6 or 6/10/6-membered core ring found in conventional taxoids such as paclitaxel or docetaxel ...
... taxoids MeSH D02.455.426.392.368.242.888.777 - paclitaxel MeSH D02.455.426.392.368.284 - cycloheptanes MeSH D02.455.426.392. ... taxoids MeSH D02.455.849.291.850.777 - paclitaxel MeSH D02.455.849.365 - dolichol MeSH D02.455.849.365.250 - dolichol ...
These two taxoids are clinically active against breast, ovarian and lung cancers. Taxoids are highly complex diterpenoids form ... These two taxoids are clinically active against breast, ovarian and lung cancers. Taxoids are highly complex diterpenoids form ... Taxoids constitute a new class of antimitotic agents different from vinca-alkaloids: on the one hand, paclitaxel and docetaxel ...
The taxoids: same roots, different drugs D D Von Hoff. Semin Oncol. 1997 Aug. ... The scientific rationale for developing taxoids. Aapro M. Aapro M. Anticancer Drugs. 1996 Aug;7 Suppl 2:33-6. Anticancer Drugs ... The two taxoids also exhibit slightly different toxicity and clinical efficacy profiles. Docetaxel-induced adverse events have ...
The systematic investigation on the roots of Taxus wallichiana has resulted in the isolation of nine taxoids-taxol 1 baccatin ... Studies on the Himalayan yew Taxus wallichiana: Part VII - The taxoids and phenolic constituents of the roots of Taxus ...
Eisenhauer EA, Vermorken JB (January 1998). "The taxoids. Comparative clinical pharmacology and therapeutic potential". Drugs. ...
Taxoids / adverse effects * Taxoids / therapeutic use* Substances * Antibodies, Monoclonal * Antineoplastic Agents * B7-H1 ...
Taxoids [therapeutic use] *Treatment Outcome. *0 (Androgen Receptor Antagonists) *0 (Taxoids) *15H5577CQD (Docetaxel) ...
Taxoids / adverse effects* * Taxoids / therapeutic use * Treatment Outcome Substances * Organometallic Compounds * Taxoids ...
Taxoids--therapeutic use. Publication Types: Webcast Rights: This is a work of the United States Government. No copyright ...
2. Taxoids in combination chemotherapy for metastatic breast cancer.. Dieras V; Fumoleau P; Bourgeois H; Misset JL; Azli N; ... Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.. DIncalci M; Schüller J; Colombo ... The scientific rationale for developing taxoids.. Aapro M. Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709. [ ...
... taxoids, e.g., paclitaxel and docetaxel gemcitabine; 6-thioguanine; mercaptopurine; platinum coordination complexes, such as ...
RESULTS: The above mentioned mass spectrometry analysis of taxoids confirmed poisoning by taxanes. The presence of taxin B/ ... Taxoids:analysis, Taxu. OBJECTIVES: Toxic effects of the yew have been known since ancient times. Yew toxicity is due to the ...
Eisenhauer, E. A., and Vermorken, J. B. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs ...
Taxoids,N0000011317, GABA Antagonists,N0000011316, Biocompatible Materials,N0000011315, Imidazolidines,N0000011314, Androgen ...
PURPOSE: A randomized phase II trial of two novel treatment strategies in the first-line management of advanced non-small-cell lung cancer patients with performance status (PS) 2. PATIENTS AND METHODS: Patients were assigned to docetaxel 30 mg/m(2) on days 1, 8, and 15 every 28 days in combination with either cetuximab 400 mg/m(2) loading dose followed by 250 mg/m(2) weekly (D + C) or bortezomib 1.6 mg/m(2) on days 1, 8, and 15 every 28 days (D + B) for up to 4 cycles. Patients with responding or stable disease continued cetuximab or bortezomib until progression. The primary end point was progression-free survival (PFS) rate at 6 months. RESULTS: Sixty-four patients were enrolled and 59 were included in this analysis. Complete or partial response rates were 13.3% and 10.3% for D + C and D + B, respectively. Median PFS was 3.4 months in the D + C arm and 1.9 months in the D + B arm. Corresponding figures for 6-month PFS were 27.8% and 13.8% and 5.0 and 3.9 months for median survival, ...
Taxoids - Preferred Concept UI. M0443608. Scope note. A group of diterpenoid CYCLODECANES named for the taxanes that were ...
Taxoids Preferred Term Term UI T528512. Date12/16/2002. LexicalTag NON. ThesaurusID NLM (2004). ... Taxoids [D02.455.426.392.368.242.888] * Docetaxel [D02.455.426.392.368.242.888.389] * Paclitaxel [D02.455.426.392.368.242. ... Taxoids Preferred Concept UI. M0443608. Registry Number. 0. Scope Note. A group of diterpenoid CYCLODECANES named for the ... Taxoids. Tree Number(s). D02.455.426.392.368.242.888. D02.455.849.291.850. Unique ID. D043823. RDF Unique Identifier. http://id ...
Taxoids Preferred Term Term UI T528512. Date12/16/2002. LexicalTag NON. ThesaurusID NLM (2004). ... Taxoids [D02.455.426.392.368.242.888] * Docetaxel [D02.455.426.392.368.242.888.389] * Paclitaxel [D02.455.426.392.368.242. ... Taxoids Preferred Concept UI. M0443608. Registry Number. 0. Scope Note. A group of diterpenoid CYCLODECANES named for the ... Taxoids. Tree Number(s). D02.455.426.392.368.242.888. D02.455.849.291.850. Unique ID. D043823. RDF Unique Identifier. http://id ...
right Western cells and letters, assigned with AvalinahsBooks and taxoids. I got a % from the economy of the jS Mestizo, ... taxoids. Lewis terminated patriarchy Shipping( Scheme 6-32). Sarcophytonin B( 67) received deeply loved from Sarcophyton spp. ... taxoids , thinking, apparatus film, Y : information, era notion, Y , parte, Eruption theme : forum, crystal body ... a few shop international relations in uncommon places indigeneity cosmology and the limits of over their patriarchal taxoids, ...
Taxoids, Transplantation, Autologous, Treatment Outcome, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial ...
taxoids. Theres more to see -- the rest of this topic is available only to subscribers. ...
Taxoids. A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on ... PaclitaxelAntineoplastic Agents, PhytogenicCarboplatinTubulin ModulatorsCisplatinTaxoidsAntineoplastic AgentsDoxorubicinBridged ... IntravenousTaxoidsLung NeoplasmsBreast NeoplasmsAntineoplastic AgentsDoxorubicinTreatment OutcomeBridged CompoundsDose-Response ...
Kitagawa, Y., Ishihara, R., Ishikawa, H., Ito, Y., Oyama, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawachi, H., Kuribayashi, S., Kono, K., Kojima, T., Takeuchi, H., Tsushima, T., Toh, Y., Nemoto, K., Booka, E., Makino, T., Matsuda, S., & 8 othersMatsubara, H., Mano, M., Minashi, K., Miyazaki, T., Muto, M., Yamaji, T., Yamatsuji, T. & Yoshida, M., 2023 7月, In: Esophagus. 20, 3, p. 343-372 30 p.. 研究成果: Article › 査読 ...
Dive into the research topics of Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Together they form a unique fingerprint. ...
Kitagawa, Y., Ishihara, R., Ishikawa, H., Ito, Y., Oyama, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawachi, H., Kuribayashi, S., Kono, K., Kojima, T., Takeuchi, H., Tsushima, T., Toh, Y., Nemoto, K., Booka, E., Makino, T., Matsuda, S., & 8 othersMatsubara, H., Mano, M., Minashi, K., Miyazaki, T., Muto, M., Yamaji, T., Yamatsuji, T. & Yoshida, M., 2023 Jul, In: Esophagus. 20, 3, p. 343-372 30 p.. Research output: Contribution to journal › Article › peer-review ...
Ganti, A. K. P., Loo, B. W., Bassetti, M., Blakely, C., Chiang, A., DAmico, T. A., DAvella, C., Dowlati, A., Downey, R. J., Edelman, M., Florsheim, C., Gold, K. A., Goldman, J. W., Grecula, J. C., Hann, C., Iams, W., Iyengar, P., Kelly, K., Khalil, M., Koczywas, M., & 14 othersMerritt, R. E., Mohindra, N., Molina, J., Moran, C., Pokharel, S., Puri, S., Qin, A., Rusthoven, C., Sands, J., Santana-Davila, R., Shafique, M., Waqar, S. N., Gregory, K. M. & Hughes, M., Dec 2021, In: JNCCN Journal of the National Comprehensive Cancer Network. 19, 12, p. 1441-1464 24 p.. Research output: Contribution to journal › Article › peer-review ...
Taxoids/administration & dosage; Treatment Outcome; ...
  • DOCEZAP 80MG INJECTION contains Docetaxel which belongs to the group of medicines called Taxoids. (netmeds.com)
  • Paclitaxel from Taxus trees is an efficient and widely used anticancer drug, however, the accumulation of taxoids and other active ingredients can vary greatly among Taxus species. (biomedcentral.com)
  • Several barriers, including low content of taxoids, exhausted natural resources and high loss rate of purification, limited the increasing of paclitaxel supply. (biomedcentral.com)
  • The genomes of Taxus species unveil novel candidates in the biosynthesis of taxoids. (mpg.de)
  • Taxoids from the himalayan yew : a potent anticancer plant. (ijpsonline.com)
  • Synthesis and protein binding of (4-carboxybutyl)carbamoyl- substituted taxoids. (mpg.de)
  • The relatively recent introduction of a new class of chemotherapeutic agents--the taxoids--has raised hope of improved survival for patients with advanced or metastatic cancer. (cancernetwork.com)
  • Exotoxins, taxoids can be made by treating with formaldehyde but treated toxins show immunogenicity. (vivadifferences.com)
  • 2. Taxoids in combination chemotherapy for metastatic breast cancer. (nih.gov)
  • Taxoids have also been used in various conjugates with different tumor-targeting modules including polyunsaturated fatty acids (PUFAs) and monoclonal antibodies, etc. (creativebiolabs.net)
  • Standards have recently been established in the adjuvant treatment of patients with gastrointestinal carcinoma, and promising new drugs, including monoclonal antibodies, thymidylate synthase, and topoisomerase inhibitors, as well as taxoids, are currently being tested in phase I, II, and III trials of gastrointestinal tumors. (ernst-dietrich-kreuser.de)
  • With the own taxoids in economic address(es and using subjects in other ebook A History of Pagan settings, it has combined potted to above wear and provide the pictures and sensitive inspiration of final Steps, never including up valuable men in the boy of female degradation thing to the interactive Survey. (surfbirder.com)
  • These two taxoids are clinically active against breast, ovarian and lung cancers. (nih.gov)
  • The combined use of EIM with PCA/HCA methodologies was able to correctly classify active and inactive taxoids with 100% of accuracy using only a few "universal" quantum molecular descriptors. (unicamp.br)
  • Taxoids are highly complex diterpenoids form natural origin. (nih.gov)
  • 1. Design, synthesis and SAR study of Fluorine-containing 3rd-generation taxoids. (nih.gov)
  • binding center in microtubules: a picosecond laser study with fluorescent taxoids. (bio-techne.com)
  • 10. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. (nih.gov)